Primary Immunodeficiency
Videja B.V. focuses on severe combined immunodeficiency linked to a genetic defect in RAG1, with research centered on restoring immune function in affected patients.
- RAG1-deficient SCID
- Inherited immune system disorders
- T-cell and B-cell deficiency
The sponsor’s clinical activity is directed toward conditions in which profound defects in adaptive immunity create early and life-threatening vulnerability to infection.
Gene Therapy
The company supports gene therapy research for a monogenic immune disorder, with interest in correcting the underlying genetic cause of disease rather than treating symptoms alone.
- Autologous hematopoietic stem cell gene therapy
- Genetic correction of RAG1 deficiency
- Immune reconstitution
This area reflects a therapeutic focus on restoring functional lymphocyte development and improving durable immune recovery in patients with inherited immunodeficiency.
Hematopoietic Stem Cell Therapy
Videja B.V. is involved in research using hematopoietic stem cells as the vehicle for delivering genetic repair in RAG1-SCID, highlighting interest in cell-based approaches to immune system rebuilding.
- Autologous stem cell treatment
- Stem cell-based immune restoration
- Long-term hematologic engraftment
The clinical emphasis is on enabling development of functional T cells and B cells through modified patient-derived cells.
Safety and Survival Outcomes
The sponsor’s research also addresses safety, tolerability, and overall survival in the setting of advanced therapy for a severe inherited immune disorder.
- Adverse event monitoring
- Short- and long-term treatment safety
- Survival in severe immunodeficiency
These interests align with the need to evaluate both clinical benefit and treatment-related risk in patients with profound immune dysfunction.
